BLOOD CHOLINESTERASE ACTIVITY AND OXIDATIVE STRESS IN TYPE 2 DIABETIC PATIENTS
Background: Type 2 diabetes mellitus is a metabolic disorder that affects functional aspects of many enzymatic systems, including those of blood cholinesterases. The aim of the present study was to assess the association between oxidative stress and blood plasma cholinesterase activities in patients with type 2 diabetes.
Subjects and methods: A total of 200 subjects (100) apparently healthy individuals and 100 type 2 diabetic patients) of both sexes (50/gender) were enrolled in this study. Their ages ranged between 30 to 70 years. The enrolled participants were not exposed to organophosphate insecticides or any medication that is known to interfere with cholinesterase activity. The criteria of WHO for diagnosis of type 2 diabetes were applied for confirming the diagnosis. Plasma malondialdehyde concentration, an oxidative stress marker and both plasma and erythrocyte cholinesterase activities were measured in all subjects.
Results: Significantly (P< 0.05) higher plasma malondialdehyde concentrations with both plasma and erythrocyte cholinesterase activities were found in type 2 diabetic patients, compared to respective healthy individuals. Plasma malondialdehyde concentrations significantly increased in both male and female type 2 diabetic patients in comparison with healthy individuals. Plasma cholinesterase activity significantly increased in type 2 diabetic male patients, whereas that of the erythrocyte significantly increased in type 2 diabetic females compared to healthy individuals’ respective values.
Conclusions: Elevated malondialdehyde concentrations in conjunction with increased blood cholinesterase activities may render type 2 diabetic patients more susceptible to oxidative stress; this might impact therapy with cholinesterase inhibitors when there is exposure to anticholinesterase pesticides.
2. Diabetes Canada Clinical Practice Guidelines Expert Committee, Punthakee Z, Goldenberg R, Katz P. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018; 42 Suppl.1:S10-S15.
3. Ighodaro OM. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother. 2018;108:656-62.
4. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharm J. 2016; 24(5): 547-53.
5. Silman I. The multiple biological roles of the cholinesterases. Prog Biophys Mol Biol. 2020; S0079-6107 (20) 30129-2. doi: 10.1016/j.pbiomolbio.2020.12.001.
6. Wilson BW. Cholinesterase inhibition. In: Wexler P, editor. Encyclopedia of Toxicology, Vol. 1, 2nd ed. New York: Elsevier Inc; 2005:588-599.
7. Cocker J, Mason HJ, Garfitt SJ, Jones K. Biological monitoring of exposure to organophosphate pesticides. Toxicol Lett. 2002; 134(1-3):97-103.
8. Wilson BW, Arrieta DE, Henderson JD. Monitoring cholinesterases to detect pesticides exposure. Chem Biol Interact. 2005; 157-158: 253-6.
9. Mohammad FK, Al-Badrany Y, Al-Jobory M. Acute toxicity and cholinesterase inhibition in chicks dosed orally with organophosphate insecticides. Arch Ind Hyg Toxicol. 2008; 59:145-51.
10. Mohammad FK, Alias AS, Ahmed OAH. Electrometric measurement of plasma, erythrocyte and whole blood cholinesterase activities in healthy human volunteers. J Med Toxicol. 2007; 3:25–30.
11. Mohammad FK, Al-Baggou B, Alias A, Faris GA-M. Application of an electrometric method for measurement of in vitro inhibition of blood cholinesterases from sheep, goats and cattle by dichlorvos and carbaryl. Vet Med. 2006; 51:45-50.
12. Han Y, Ma Y, Liu Y, Zhao Z, Zhen S, Yang X, et al. Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction. Diabetes Metab Syndr Obes. 2019; 12: 685-702.
13. Mousa SO, Sayed SZ, Moussa MM, Hassan AH. Assessment of platelets morphological changes and serum butyrylcholinesterase activity in children with diabetic ketoacidosis: a case control study. BMC Endocr Disord. 2017; 17(1): 23. doi: 10.1186/s12902-017-0174-6.
14. Mushtaq G, Greig NH, Khan JA, Kamal MA. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014; 13(8): 1432-9.
15. Ragoobirsingh D, Bharaj BS, Morrison EY. Change in serum cholinesterase activity in Jamaican diabetics. J Nat Med Assoc. 1992;84:853-5.
16. 16. Rao AA, Sridhar GR, Das UN. Elevated Butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease. Med Hypoth. 2007; 69: 1272-6.
17. Jewad AM, Yasser OM, Awad NAN. Evaluation of serum cholinesterase activity, lipid peroxidation and lipids profile in type 2 diabetes mellitus. Iraqi Nat J Chem. 2011; 42: 283-9.
18. Sato KK, Hayashi T, Maeda I, Koh H, Harita N, Uehara S, et al. Serum butyrylcholinesterase and the risk of future type 2 diabetes: the Kansai Healthcare Study. Clin Endocrinol (Oxf). 2014; 80(3): 362-7.
19. Suhail M, Rizvi SI. Erythrocyte membrane acetylcholinesterase in type 1 (insulin-dependent) diabetes mellitus. Biochem J. 1989; 259: 897-979.
20. Rizvi SI, Zaid MA. Insulin‐like effect of (–) epicatechin on erythrocyte membrane acetylcholinesterase activity in type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2001; 28:776-8.
21. Ahmed AS. Effect of acetylcholine activity on some blood parameters in diabetic patients. Neuroquantology. 2020; 18: 35-8.
22. Garcia CC, Potian JG, Hognason K, Thyagarajan B, Sultatos LG, Souayah N, et al. Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy. Am J Physiol Endocrinol Metab. 2012; 303(4): E551-61.
23. Rashid HM, Mohammad FK, Persike DS. In vitro inhibition of blood cholinesterases by the organophosphate dichlorvos in typ-2 diabetic patients. Indian J Foren Med Toxicol. 2021 (in press).
24. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019; 576:51–60.
25. Inácio Lunkes G, Stefanello F, Sausen Lunkes D, Maria Morsch V, Schetinger MR, Gonçalves JF. Serum cholinesterase activity in diabetes and associated pathologies. Diabetes Res Clin Prac. 2006; 72: 28-32.
26. Patel BN, Mackness MI, Harty DW, Arrol S, Boot-Hanford RP, Durrington PN. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta. 1999; 1035: 113-6.
27. Hegazy AM, Abdel Azeem AS, Shahy EM, El-Sayed EM. Comparative study ofcholinergic and oxidative stress biomarkers in brains of diabetic and hypercholesterolemic rats. Hum Exp Toxicol. 2016; 35(3): 251-8.
28. Tvarijonaviciute A, Ceron JJ, Caldin M. Serum butyrylcholinesterase activity in dogs with diabetes mellitus. Vet J. 2012; 192(3): 494-7.
29. Krajewska E, Zavodnik I, Kluska B, Szosland K, Bryszewska M. Acetylcholinesterase activity of normal and diabetic human erythrocyte membranes: the effect of oxidative agents. Biochem Mol Biol Int.1997; 42(1): 203-10.
30. WHO. Classification of diabetes mellitus. Geneva: WHO; 2019.
31. Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol. 1978; 52: 302-10.
32. Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7: 88-95.
33. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019; 70: 809-24.
34. Yepes-Calderón M, Sotomayor CG, Gomes-Neto AW, Gans RO, Berger SP, Rimbach G, et al. Plasma malondialdehyde and risk of new-onset diabetes after transplantation in renal transplant recipients: a prospective cohort study. Clin Med. 2019; 8(4): 453.
35. Aouacheri O, Saka S, Krim M, Messaadia A, Maidi IJ. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Can J Diabetes. 2015; 39(1): 44-9.
36. Özbay B, Dülger H. Lipid peroxidation and antioxidant enzymes in Turkish population: relation to age, gender, exercise, and smoking. Tohoku J Exp Med. 2002; 197(2): 119-24.
37. Gil L, Siems W, Mazurek B, Gross J, Schroeder P, Voss P, et al. Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res Commun. 2006; 40(5): 495-505.
38. Kowalska K, Milnerowicz H. The influence of age and gender on the pro/antioxidant status in young healthy people. Ann Clin Lab Sci. 2016; 46(5): 480-8.
39. Dalmolin SP, Dreon DB, Thiesen FV, Dallegrave E. Biomarkers of occupational exposure to pesticides: systematic review of insecticides. Environ Toxicol Pharmacol. 2020; 75: 103304. doi: 10.1016/j.etap.2019.103304.
40. Karami-Mohajeri S, Abdollahi M. Toxic influence of organophosphate, carbamate, and organochlorine pesticides on cellular metabolism of lipids, proteins, and carbohydrates: a systematic review. Hum Exp Toxicol. 2011; 30(9): 1119-40.
41. Mahmood AA, Khalaf MM, Zainal AA. Cholinesterases activities in diabetic and hyperlipidemic patients. Indian J Public Health Res Dev. 2020; 11(4): 1833-7.
42. Das UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007; 13(12): 214-21.
43. Al-Baggou BK, Naser AS, Mohammad FK. Hydrogen peroxide potentiates organophosphate toxicosis in chicks. Hum Vet Med Bioflux. 2011; 3:142-9.
44. Pearson JN, Patel M. The role of oxidative stress in organophosphate and nerve agent toxicity. Ann NY Acad Sci. 2016;1378:17–24.